

*Short communications***Haemoglobinopathies: a pitfall in the assessment of glycosylated haemoglobin by ion-exchange chromatography**C. Eberentz-Lhomme<sup>1</sup>, R. Ducrocq<sup>2</sup>, S. Intrator<sup>2</sup>, J. Elion<sup>2</sup>, E. Nunez<sup>2</sup> and R. Assan<sup>1</sup>Departments of <sup>1</sup>Diabetes and <sup>2</sup>Biochemistry, Hôpital Bichat, Paris, France

**Summary.** Total glycosylated haemoglobin was determined by a minicolumn ion-exchange chromatography technique (Bio-Rad) and correlated with the mean of fasting and post-prandial blood glucose values for the preceding 6 weeks. In 360 diabetic subjects, free of congenital haemoglobinopathies and other detected causes of haemoglobin A<sub>1</sub> misinterpretation (reference diabetic group), a highly significant correlation was established between haemoglobin A<sub>1</sub> and glucose ( $y = 0.54 \times + 4.91$ ;  $r = 0.791$ ;  $p < 0.01$ ). In 28 of the 29 patients with heterozygous haemoglobinopathies (HbS, C, D, E), the

apparent haemoglobin A<sub>1</sub> values were lower than expected according to the 95% confidence limits of the diabetic reference group. The apparent haemoglobin A<sub>1</sub> value was above these limits in patient 29, with  $\beta$  thalassaemia. Patients with inappropriate glycosylated haemoglobin values should be investigated for causes of haemoglobin A<sub>1</sub> misinterpretation, in particular, haemoglobinopathies.

**Key words.** Glycosylated haemoglobin, haemoglobinopathies S, C, D, E,  $\beta$  thalassaemia, diabetes.

The determination of glycosylated haemoglobin (HbA<sub>1c</sub>) has become a widely used index for the assessment of diabetic control [1]. The rapid determination by minicolumn chromatography of a fast migrating group of fractions, termed HbA<sub>1</sub>, is convenient and readily available [2]. Erroneous interpretations may be due to various pathophysiological and pharmacological interferences [3].

The aim of the present study was to define how the measurement of HbA<sub>1</sub> is affected by the presence of congenitally abnormal haemoglobins [4–10].

**Subjects and methods***Subjects*

A total of 389 diabetic subjects were studied: 360 were free of congenitally abnormal haemoglobin (diabetic reference group); 29 others had congenital haemoglobinopathy, as described below. Both groups were similar in age ( $45 \pm 5$  versus  $50 \pm 5$  years; mean  $\pm$  SEM), sex ratio (190/170 versus 18/11) and the percentage of insulin dependence (50% versus 55%). Patients with either recurrent hypoglycaemia, shortened erythrocyte life-span or renal failure were excluded.

*Laboratory methods*

**HbA<sub>1</sub>.** The HbA<sub>1</sub> fraction was determined by a rapid minicolumn chromatography technique (Bio-Rad, Richmond, California, USA). The heparinized venous blood samples were haemolyzed with poly-

oxyethylene ether 0.33% (v/v), put on the Biorex resin column (25 mm  $\times$  7 mm, Bio-Rad), then eluted at  $22 \pm 1^\circ\text{C}$  with phosphate buffer (pH 6.7, 0.01 mol/l). The optical density of eluates was read at 415 nm. The percentage of HbA<sub>1</sub> was calculated in comparison with total haemoglobin. The HbA<sub>1</sub> value, measured in 30 non-diabetic subjects, was  $6.7 \pm 0.7\%$  of total haemoglobin.


**Haemoglobin studies:** Electrophoresis was performed by two different migrating systems [11], both from Helena, Beaumont, Texas: (1) on cellulose acetate plates using a Tris/EDTA/boric acid buffer (pH 8.6), and (2) on agar gel with a citrate/citric acid buffer (pH 6.0).

Further identification of HbS was made by a precipitation test [12]. Heterozygous thalassaemia was diagnosed by the typical haematological (microcytosis) and electrophoretic patterns: high HbA<sub>2</sub> (9%) and HbF (3%), and the alkaline denaturation test [13]. The variants HbD and HbE were identified by direct structural analysis according to established techniques [14–15]. In all cases the variant was present in the heterozygous state and the abnormal fraction amounted to 31–44% of the total haemoglobin.

**Blood glucose.** This was measured on heparinized venous blood samples by a glucose-oxidase technique (Boehringer, Mannheim, FRG).

**Calculations.** A mean blood glucose value was calculated in each patient from 6–15 fasting and post-prandial determinations for the preceding 6 weeks. The regression line of the HbA<sub>1</sub> versus glucose values and the corresponding 95% confidence limits were calculated from the data relative to the 360 reference diabetic patients.

**Statistical analysis.** The regression lines were calculated according to classical methods [16].



**Fig. 1.** Apparent HbA<sub>1</sub> values in the patients with haemoglobinopathies. The hatched area and regression line correspond to the diabetic reference group and its 95% confidence limits. The individual HbA<sub>1</sub> values are shown from patients with haemoglobin S (▲), C (●), D (○), E (\*) and thalassaemia (★)

## Results

### *HbA<sub>1</sub> and glucose correlation*

In the reference diabetic group, there was a significant correlation between the HbA<sub>1</sub> and glucose values (Fig. 1; the equation of the regression line was:  $y = 0.54x + 4.91$ ;  $r = 0.791$ ;  $n = 360$ ;  $p < 0.01$ ). No significant change in slope coefficient appeared when this was calculated for successive 2.7 mmol/l glucose ranges.

In the patients with haemoglobinopathies (HbS,  $n = 17$ ; HbC,  $n = 8$ ; HbD Punjab,  $n = 1$ ; HbE,  $n = 2$ ;  $\beta$  thalassaemia,  $n = 1$ ), all apparent HbA<sub>1</sub> values were outside the 95% confidence limits constructed from the reference group. In the patients with C, D, E and S haemoglobins, the measured HbA<sub>1</sub> values fell below these limits. A good correlation was found between these apparent HbA<sub>1</sub> values and the corresponding glucose concentration. However, the slope of the regression line was shallower than for the reference group ( $y = 0.30x + 2.50$ ). In contrast, in the patient with heterozygous  $\beta$  thalassaemia (with HbF and A<sub>2</sub>), the HbA<sub>1</sub> value was above these limits.

The inspection of chromatography columns readily detected the abnormal haemoglobins C, D and S. The fractions D and S appeared as slow migrating bands with a  $r_f$  approximately half that of normal haemoglobin (HbA<sub>0</sub>). The C fraction presented as a thin band which stuck to the top of the column. In the  $\beta$ -thalassaemic patient, HbF was not detected by the examination of the columns, since it moved faster than HbA<sub>0</sub>, and co-eluted with the HbA<sub>1</sub> fraction.

## Discussion

A highly significant correlation was found between HbA<sub>1</sub> and glucose concentration in the reference diabetic group. The patients with haemoglobinopathies had values outside the 95% confidence limits. The presence of haemoglobins S, C, D, E led to the under-estimation of HbA<sub>1</sub> and overestimation in a patient with thalassaemia. The haemoglobins S, C, D and E are more positively charged compared with HbA, hence elution from the cation exchange resin is retarded. The fast-moving fraction then corresponds only to the glycosylated HbA, which represents only a part of total haemoglobin [17–20]. Conversely, HbF is more negatively charged than HbA and co-eluates with HbA<sub>1c</sub> on cation exchange chromatography, leading to an over-estimation of this fraction [21]. The same occurs with the rare, fast-moving variants HbK, I, J, with HbH in some  $\beta$  thalassaemia patients [20–22] and HbF in patients with  $\beta$  thalassaemia, hereditary persistence of fetal haemoglobin and acquired HbF [23].

The concept of haemoglobin variants interfering with the measurement of glycosylated haemoglobin by ion exchange chromatography is not new [1, 24]. However, this problem has not received wide attention. It was a potential cause of misinterpretation in 6.9% of our patients, due to the large number of patients from countries with a high prevalence of haemoglobinopathies. Since the HbA<sub>1</sub> assay has been proposed for the screening of diabetes among large population groups [19], the interference of haemoglobin variants with this determination must be known, particularly in ethnic groups with a high incidence of haemoglobin variants. It is of interest that HbA<sub>1</sub> measurements in diabetic patients led to the description of two hitherto undescribed haemoglobin variants [25, 26]. In diabetic subjects with congenitally abnormal haemoglobin, the percentage of a haemoglobin variant can be measured by electrophoresis, thus allowing corrections of HbA<sub>1</sub> values. However, it may be advisable, in such patients, to measure haemoglobin glycosylation by either chemical methods or affinity chromatography on aminophenyl boronic acid resins [27].

*Acknowledgments.* We thank Pr. J. Lellouch and Mrs E. Patois (INSERM U 169) for expert assistance in the statistical analysis; Mrs M. J. Clergé and the nursing staff, and Mrs I. Herckla and M. Th. Dalle for technical assistance and D. Boillot for editorial help. This work was supported by a grant from Université Xavier Bichat.

## References

1. Bunn HF (1981) Evaluation of glycosylated haemoglobin in diabetic patients. *Diabetes* 30: 613–617
2. Jones MB, Koler RD, Jones RT (1978) Micro-column method for the determination of haemoglobin minor fractions A<sub>1</sub> (a + b) and A<sub>1c</sub>. *Hemoglobin* 2: 53–58
3. Hammons GT, Junger K, McDonald JM, Ladenson JH (1982) Evaluation of three minicolumn procedures for measuring hemoglobin A<sub>1</sub>. *Clin. Chem.* 28: 1775–1778

4. Aleyassine H (1979) Low proportions of glycosylated hemoglobin associated with hemoglobin S and hemoglobin C. *Clin Chem* 25: 1484–1486
5. Fitzgerald MD, Cauchi MN (1980) Glycosylated hemoglobins in patients with a hemoglobinopathy. *Clin Chem* 26: 360–361 (Letter)
6. Tegos C, Rahbar S, Blume K, Johnson C, Beutler E (1981) Glycosylated minor C, D and E hemoglobins. *Biochem Med* 26: 121–125
7. Choo-Kang E, Campbell M, Anderson J (1981) The measurement of glycosylated haemoglobins by the cation exchange chromatographic method in subjects with abnormal haemoglobins. *West Indian Med J* 30: 188–192
8. Deledda R, Inzaina A, Demuro P, Dibeltulo P (1981) Behaviour of glycosylated hemoglobin in non-diabetic beta-thalassaemia trait carriers. *Quad Scavo Diagn* 177: 316–321
9. Jonah MH, Trinh M, Krauss JS (1982) Interference by fast hemoglobin variants in the column-chromatographic assay for glycosylated hemoglobin. *Clin Chem* 28: 1250 (Letter)
10. Menard L, Dempsey ME, Blankstein LA, Aleyassine H, Wacks M, Soeldner JS (1980) Quantitative determination of glycosylated hemoglobin A<sub>1c</sub> by agar gel electrophoresis. *Clin Chem* 26: 1598–1602
11. Basset P, Braconnier F, Rosa J (1982) An update on electrophoretic and chromatographic methods in the diagnosis of hemoglobinopathies. *J Chromatogr* 227: 267–304
12. Nalbandian RM, Nichols BM, Camp FR, Lusher JM, Conte NF, Henry RT (1971) Dithionite tube test. A rapid inexpensive technique for the detection of hemoglobin S and non-S sickling hemoglobin. *Clin Chem* 17: 1028–1032
13. Singer K, Chernoff AI, Singer L (1951) Studies on abnormal hemoglobins. I – Their demonstration in Sick cell anemia and other hematologic disorders by means of alkali denaturation. *Blood* 6: 413–420
14. Clegg JB, Naughton NA, Weatherall DJ (1966) Abnormal human haemoglobins: separation and characterization of the  $\alpha$  and  $\beta$  chains by chromatography, and the determination of two new variants: Hb Chesapeake and HbJ Hong-Kong. *J Mol Biol* 19: 91–108
15. Boissel JP, Wajcman H, Fabritius H, Cabannes R, Labie D (1981) Application of high performance liquid chromatography to abnormal hemoglobin studies. Characterization of HdD in Ivory-Coast and description of new variant Hb: Cocodi 21 (B3) Asp – Asn *Biochem Biophys Acta* 660: 203–210
16. Schwartz D (1969) Méthodes statistiques à l'usage des médecins et des biologistes. Flammarion, Paris
17. Aleyassine H (1980) Glycosylation of hemoglobin S and hemoglobin C. *Clin Chem* 26: 526–527
18. Abdella PM, Ritchey JM, Klotz IM (1977) Glycosylation of hemoglobin S by reducing sugars and its effect on gelation. *Biochem Biophys Acta* 490: 462–470
19. Abraham EC, Stallings M, Cameron BF, Huisman TH (1980) Minor hemoglobins in sickle-cell heterozygotes and homozygotes with and without diabetes. *Biochem Biophys Acta* 625: 109–117
20. Bernstein RE (1980) Glycosylated hemoglobins: hematologic considerations determine which assay for glycohemoglobin is advisable. *Clin Chem* 26: 174–175
21. Tegos C, Beutler E (1980) Glycosylated hemoglobin A<sub>2</sub> components. *Blood* 56: 571–572
22. Krause JR, Stolc V, Campbell E (1982) The effect of hemoglobin F upon glycosylated hemoglobin determinations. *Am Soc Clin Pathol* 78: 767–769
23. Kruiswijk T, Diaz DP, Holthamp HC (1981) Interference of hemoglobin H in the column chromatographic assay of glycosylated hemoglobin A. *Clin Chem* 27: 641–642
24. Sosenko JM, Fluckiger R, Platt OS, Gabbay KH (1980) Glycosylation of variant hemoglobins in normal and diabetic subjects. *Diabetes Care* 3: 590–593
25. Wajcman H, Elion J, Boissel JP, Labie D, Jos J, Girot R (1982) A silent hemoglobin variant/hemoglobin Necker-Enfants-Malades  $\alpha$ 20 (B<sub>1</sub>) His – Tyr. *Hemoglobin* 4: 177–184
26. Puukka R, Hekali R, Akerblom HK, Kear ML, Dukes M, Lehman H (1982) Haemoglobin Hijiyama: a haemoglobin variant found in connection with glycosylated haemoglobin estimation in a Finnish diabetic boy. *Clin Chim Acta* 121: 51–57
27. Klenk DC, Hermanson GT, Krohn RI, Fujimoto EK, Mallia AK, Smith PK, England JD, Wiemeyer HM, Little RR, Goldstein DE (1982) Determination of glycosylated hemoglobin by affinity chromatography: comparison with colorimetric and ion-exchange methods, and effects of common interferences. *Clin Chem* 28: 2088–2094

Received: 25 May 1984  
and in revised form: 8 October 1984

Dr. Roger Assan  
Diabetes Department  
Hôpital Bichat  
46 rue Henri Huchard  
F-75018 Paris  
France